The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

parthenontx.com

Founded Year

2019

Stage

Series A | Alive

Total Raised

$65M

Last Raised

$65M | 6 mos ago

About Parthenon Therapeutics

Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME).

Parthenon Therapeutics Headquarter Location

One Broadway

Cambridge, Massachusetts, 02142,

United States

781 898 5627

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Parthenon Therapeutics Patents

Parthenon Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Fluoroarenes
  • Hepatotoxins
  • Indoles
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/19/2021

Indoles, Hepatotoxins, Psychiatric diagnosis, Syndromes, Fluoroarenes

Application

Application Date

2/19/2021

Grant Date

Title

Related Topics

Indoles, Hepatotoxins, Psychiatric diagnosis, Syndromes, Fluoroarenes

Status

Application

Latest Parthenon Therapeutics News

J&J cell therapy head exits to take up post at fledgling biotech

Dec 1, 2021

Tamas Oravecz, Ph.D., chief scientific officer at Parthenon Therapeutics (Business Wire) Johnson & Johnson has lost its global head, cell therapy platform and discovery. Tamas Oravecz, Ph.D., took up the post at J&J’s Janssen earlier this year, only to leave to become chief scientific officer  at the newly minted cancer biotech Parthenon Therapeutics. Oravecz worked on HIV cell and gene therapies early in his career, spending two years at Novartis as it tried to make a success of the assets it acquired in the takeover of SyStemix. Later, Oravecz worked on other modalities, first during a 14-year stint at Lexicon Pharmaceuticals and later in a shorter spell at Celgene. In 2018, Oravecz joined Janssen from Celgene, initially as senior director and head of exploratory discovery. Oravecz moved roles within Janssen earlier this year, taking on the titles of VP and global head, cell therapy platform and discovery, and has now moved out of the company altogether. Last month, Oravecz left Janssen to become CSO at Parthenon. The position gives Oravecz a starring role in Parthenon’s attempt to improve the treatment of cancers by creating holes in the barriers that surround many tumors, thereby allowing T cells to penetrate the inner sanctum and wipe out the malignant cells.

Parthenon Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Parthenon Therapeutics Rank

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.